Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Exemestane
DRUG: Goserelin
DRUG: Carboplatin

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]